ESPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Esperion Therapeutics Inc (ESPR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, positive analyst sentiment, and technical indicators suggest potential upside. While there are no immediate trading signals or recent news catalysts, the stock's fundamentals and analyst confidence make it a solid long-term investment opportunity.
The technical indicators for ESPR are moderately bullish. The MACD is positive and contracting, suggesting a potential upward trend. The RSI is neutral at 58.078, indicating no overbought or oversold conditions. Moving averages are bullish, with SMA_5 > SMA_20 > SMA_200. Key support and resistance levels are S1: 3.222, Pivot: 3.422, R1: 3.623, suggesting the stock is trading near its pivot point.
Analyst David Amsellem from Piper Sandler initiated coverage with an Overweight rating and a $9 price target, citing strong growth potential for the company's bempedoic acid franchise.
Revenue increased by 69.10% YoY in Q3 2025, indicating robust growth.
Technical indicators and moving averages are bullish.
Gross margin dropped by -20.76% YoY, which could indicate rising costs or pricing pressures.
No recent news or congress trading data to act as immediate catalysts.
The stock price has shown slight declines in the regular market (-1.40%) and pre-market (-0.56%).
In Q3 2025, the company reported revenue growth of 69.10% YoY, reaching $87.31M. Net income improved by 6.13% YoY to -$31.33M, and EPS increased by 6.67% YoY to -0.16. However, gross margin declined by -20.76% YoY to 52.71%.
Piper Sandler initiated coverage with an Overweight rating and a $9 price target. The analyst expressed confidence in the company's bempedoic acid franchise for hypercholesterolemia and cardiovascular risk reduction, citing wide label approval, evolving clinical guidelines, and payer access as key growth drivers.
